Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies
NCT00990717
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
8
Enrollment
OTHER
Sponsor class
Conditions
Leukemia
Lymphoma
Myeloma
Hodgkin's Disease
Interventions
BIOLOGICAL:
NK-92 cells
Sponsor
University Health Network, Toronto